• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Circ Rep . Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on the Severity and the Mortality of Acute Myocardial Infarction in Japan - A

tetano

Editor, Senior Moderator
Circ Rep


. 2024 May 9;6(6):191-200.
doi: 10.1253/circrep.CR-24-0011. eCollection 2024 Jun 10. Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on the Severity and the Mortality of Acute Myocardial Infarction in Japan - Analysis From the JROAD-DPC Database

Mitsukuni Kimura[SUP] 1 [/SUP], Tetsuya Matoba[SUP] 1 [/SUP], Yasuhiro Nakano[SUP] 1 [/SUP], Shunsuke Katsuki[SUP] 1 [/SUP], Kazuo Sakamoto[SUP] 1 [/SUP], Masaaki Nishihara[SUP] 1 [/SUP], Takuya Nagata[SUP] 1 [/SUP], Yoshio Tahara[SUP] 2 [/SUP], Ken Nagao[SUP] 3 [/SUP], Hiroyuki Okura[SUP] 4 [/SUP], Takanori Ikeda[SUP] 5 [/SUP], Michikazu Nakai[SUP] 6 [/SUP], Hiroyuki Tsutsui[SUP] 1 [/SUP]



Affiliations
Abstract

Background: Coronavirus disease 2019 (COVID-19) has impacted on cardiovascular disease. However, it remains unclear whether the COVID-19 pandemic has impacted on disease severity and patients' prognosis of acute myocardial infarction (AMI) in Japan. Methods and Results: We retrospectively accumulated data from the Japanese Registry of All Cardiac and Vascular Diseases-Diagnosis Procedure Combination (JROAD-DPC) study (April 2019 to March 2021). Patients were divided into a before COVID-19 pandemic group or a during COVID-19 pandemic group. The proportion of patients who presented with cardiogenic shock (Killip class IV) was compared between groups, in association with 30-day mortality as the primary outcome. Killip class IV AMI significantly increased in the during COVID-19 pandemic group (15.7% vs. 14.5% in the before pandemic group, P<0.0001). The 30-day mortality was higher in the during COVID-19 pandemic group (9.6% vs. 9.2% in the before COVID-19 pandemic group, P=0.049). However, there was no significant difference in the adjusted 30-day mortality in each Killip class between the before and during COVID-19 pandemic groups. Conclusions: During the early stage of the COVID-19 pandemic in Japan, 30-day mortality of AMI increased, mainly because of the increase of Killip class IV AMI patients. However, irrespective of the COVID-19 pandemic, the adjusted 30-day mortality of each Killip classification group was unchanged.

Keywords: Acute coronary syndrome; Acute myocardial infarction; Cardiovascular disease.

 
Back
Top Bottom